"Remember when SQ Herceptin was first discussed with doctors and hospitals in the US 5 years ago there was an outcry about lost revenues and profits from the switch from IV to SQ and threats to switch away from Roche products if it was introduced. Hardly a word about patients benefits!"
I don't remember and maybe I am too naive about this. But is this a realistic concern in today's healthcare climate? Will the government, insurance companies and patients let doctors and hospitals get away with it?
News 
Market Data 
Discover 
